NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT04055844 2023-11-07Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDSMasonic Cancer Center, University of MinnesotaPhase 2 Completed14 enrolled 20 charts
NCT02587598 2021-12-08Study of INCB053914 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated97 enrolled 40 charts